BioCentury | Oct 8, 2019

Novel targets induce cardiomyocyte regeneration

...CCL24 or IGF2BP3 could restore cardiac function following MI. RNA-seq analysis identified 874 genes including CCL24...
...8, when cardiac tissue is no longer regenerative. Overexpression of CCL24 or IGF2BP3 or recombinant CCL24...
...fibrosis and ventricular dilation (see "Stimulating Heart Regeneration Following Injury" ). TARGET/MARKER/PATHWAY: Chemokine CC motif ligand 24 (CCL24; MPIF2; Eotaxin-2...
BioCentury | Oct 3, 2019
Targets & Mechanisms

Stimulating heart regeneration following injury

...Olson’s team at UTSW identified via transcriptomic and epigenomic profiling over 800 up-regulated genes including CCL24...
...MI at postnatal day 1 compared with postnatal day 8. Overexpressing either gene or delivering CCL24...
...proliferation to inhibit scarring; and enhancing angiogenesis and macrophage infiltration. Targets: CCL24 - chemokine CC motif ligand 24 (MPIF2; Eotaxin-2...
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
BioCentury | Dec 8, 2017
Financial News

OrbiMed , Thiel lead ChemomAb's $10M series B

...The mAb targets and blocks chemokine CC motif ligand 24 (CCL24; MPIF2; Eotaxin-2). ChemomAb Ltd., Tel Aviv, Israel Chris Lieu CM101 ChemomAb Ltd. Chemokine CC motif ligand 24 (CCL24) (MPIF2) (Eotaxin-2)...
BioCentury | Dec 4, 2017
Financial News

OrbiMed, Thiel lead ChemomAb's $10M series B

...diseases, including non-alcoholic steatohepatitis (NASH). The mAb targets and blocks chemokine CC motif ligand 24 (CCL24; MPIF2; Eotaxin-2). Chris Lieu CM101 ChemomAb Ltd. Chemokine CC motif ligand 24 (CCL24) (MPIF2) (Eotaxin-2)...
BioCentury | Nov 30, 2017
Clinical News

Immune Pharmaceuticals reports additional Phase II data for bertilimumab in bullous pemphigoid

In September, Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) reported additional data from 6 patients with moderate to severe bullous pemphigoid in a Phase II trial showing that IV bertilimumab (CAT-213, iCo-008) led to a decline in...
BioCentury | Mar 17, 2017
Clinical News

Bertilimumab: Preliminary Ph II data

Preliminary data from 3 patients with moderate to extensive bullous pemphigoid in an open-label, U.S. and Israeli Phase II trial showed that 10 mg/kg IV bertilimumab on days 0, 14 and 28 led to a...
BioCentury | Sep 12, 2016
Emerging Company Profile

Age factors

Alkahest Inc. is identifying factors in human plasma that could serve as therapeutics or novel targets used to treat age-related conditions, including Alzheimer's disease. The newco's work stems from the lab of co-founder Tony Wyss-Coray,...
BioCentury | Apr 4, 2016
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Yrs cash pre-cut Cash date 12-mo op loss ended 12/31 1/7/16 Sequenom Inc. (NASDAQ:SQNM) 20% to 390 $76.2 9.65 12/31/15 $7.9 Sequenom restructured to focus on women's health...
BioCentury | Feb 8, 2016
Company News

iCo ophthalmic, autoimmune, infectious news

iCo terminated all employees to preserve cash. In 2014, iCo reported that iCo-007 failed in a Phase II trial to treat diabetic macular edema (DME). The company said it has since conducted “an exhaustive search...
Items per page:
1 - 10 of 52